Clearance of Hydromorphone ER is Predictable and Stable Over Time
John Thipphawong, MD, from Janssen Pharmaceuticals, Fremont, CA, and colleagues reported at PAINWeek 2012 that the clearance of OROS hydromorphone extended-release (ER) is predictable, stable over time, and not markedly impacted by most demographic characteristics in patients with chronic osteoarthritis pain.